Minerva Neurosciences (NERV) Enterprise Value Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.34% |
| Dec 31, 2025 | -33.47% |
| Sep 30, 2025 | 32.52% |
| Jun 30, 2025 | 32.48% |
| Mar 31, 2025 | 31.89% |
| Dec 31, 2024 | 26.52% |
| Sep 30, 2024 | 25.99% |
| Jun 30, 2024 | 25.30% |
| Mar 31, 2024 | 24.22% |
| Dec 31, 2023 | -17.23% |
| Sep 30, 2023 | -12.95% |
| Jun 30, 2023 | -17.06% |
| Mar 31, 2023 | -6.18% |
| Dec 31, 2022 | 8.91% |
| Sep 30, 2022 | -1.99% |
| Jun 30, 2022 | -21.28% |
| Mar 31, 2022 | -21.48% |
| Dec 31, 2021 | -2.44% |
| Sep 30, 2021 | 9.08% |
| Jun 30, 2021 | -2.61% |
| Mar 31, 2021 | -21.06% |
| Dec 31, 2020 | 41.65% |
| Sep 30, 2020 | 30.40% |
| Jun 30, 2020 | 25.29% |
| Mar 31, 2020 | -22.13% |
| Dec 31, 2019 | 17.94% |
| Sep 30, 2019 | 25.48% |
| Jun 30, 2019 | 33.97% |
| Mar 31, 2019 | 11.72% |
| Dec 31, 2018 | -16.05% |
| Sep 30, 2018 | -32.60% |
| Jun 30, 2018 | -24.80% |
| Mar 31, 2018 | 4.67% |
| Dec 31, 2017 | -90.47% |
| Sep 30, 2017 | -59.96% |
| Jun 30, 2017 | -444.70% |
| Mar 31, 2017 | -97.70% |
| Dec 31, 2016 | -257.36% |
| Sep 30, 2016 | -337.05% |
| Jun 30, 2016 | -303.09% |